<body><a name="drugname"></a><table class="topbox" width="100%">
<tr>
<td><span class="topboxgenname">IMIPENEM-CILASTATIN SODIUM <img border="0" src="../images/pr.gif"/></span><br/>(i-mi-pen'em sye-la-stat'in)<br/><span class="topboxtradename">Primaxin<br/></span><b>Classifications:</b> <span class="classification">antiinfective</span>; <span class="classification">beta-lactam antibiotic</span><br/><b>Pregnancy Category: </b>C<br/></td>
</tr>
</table>
<h1><a name="avail">Availability</a></h1>
<p>250 mg, 500 mg, 750 mg vials</p>
<h1><a name="action">Actions</a></h1>
<p>Fixed combination of imipenem, a beta-lactam antibiotic, and cilastatin. Action of imipenem: inhibition of mucopeptide synthesis
         in bacterial cell walls leading to cell death. Cilastatin increases the serum half life of imipenem.
      </p>
<h1><a name="therapef">Therapeutic Effects</a></h1>
<p>Acts synergistically with aminoglycoside antibiotics against some isolates of <i>Pseudomonas aeruginosa.</i> Infections resistant to cephalosporins, penicillins, and aminoglycosides have responded to treatment with this combination.
      </p>
<h1><a name="uses">Uses</a></h1>
<p>Treatment of serious infections caused by susceptible organisms in the urinary tract, lower respiratory tract, bones and joints,
         skin and skin structures; also intraabdominal, gynecologic, and mixed infections; bacterial septicemia and endocarditis.
      </p>
<h1><a name="contrain">Contraindications</a></h1>
<p>Hypersensitivity to any component of product, multiple allergens. Safe use in pregnancy (category C) is not established.</p>
<h1><a name="precaution">Cautious Use</a></h1>
<p>Lactation; patients with CNS disorders (e.g., seizures, brain lesions, history of recent head injury); renal impairment; patients
         with history of penicillin allergies.
      </p>
<h1><a name="rtedsg">Route &amp; Dosage</a></h1>
<table cellpadding="4" cellspacing="0" class="rdbox" width="100%">
<tr>
<td><span class="indicationtitle">Serious Infections</span><br/><span class="rdage">Adult:</span> <span class="rdroute">IV</span> 250500 mg infused over 2030 min q68h, up to 1 g infused over 4060 min q6h  <span class="rdroute">IM</span>  500 or 750 mg q12h<br/><span class="rdage">Child:</span> <span class="rdroute">IV</span> 1015 mg/kg q6h  <span class="rdroute">IM</span> 1525 mg/kg q12h<br/><span class="rdage">Neonate:</span> <span class="rdroute">IV</span> 2040 mg/kg/d divided q1224h<br/><br/><span class="impairmenttitle">Renal Impairment</span><br/>Cl<sub>cr</sub> 2030 mL/min, dose q812h; <br/></td>
</tr>
</table>
<h1><a name="admintn">Administration</a></h1>
<ul>
<li>Caution: IM and IV solutions are <small>NOT</small> interchangeable; do <small>NOT</small> give IM solution by IV, and do <small>NOT</small> give IV solution as IM.
         </li>
</ul><span class="adminroutetype">Intramuscular</span><br/><ul>
<li>Reconstitute powder for IM injection as follows: Add 2 mL or 3 mL of 1% lidocaine HCl solution without epinephrine, respectively,
            to the 500 mg vial or the 750 mg vial. Agitate to form a suspension then withdraw and inject entire contents of the vial IM.
         </li>
<li>Give IM suspension by deep injection into the gluteal muscle or lateral thigh.</li>
<li>Use reconstituted IM injection within 1 h after preparation.</li>
</ul>
<table cellpadding="4" cellspacing="0" class="ivbox" width="100%">
<tr>
<td><span class="ivtitle">Intravenous</span><p><span class="routemethod">PREPARE:</span> <span class="methodtype">Intermittent:</span>  Dilute each dose with 10 mL of D5W, NS, or other compatible infusion solution. Agitate the solution until clear. Color should range from colorless to yellow. Further dilute with 100 mL of same solution used for initial dilution. 
               </p>
<p><span class="routemethod">ADMINISTER:</span> <span class="methodtype">Intermittent:</span> Give each 500 mg or fraction thereof over 2030 min. <small>DO NOT</small> give as a bolus dose. Nausea appears to be related to infusion rate, and if it presents during infusion, slow the rate (occurs
                  most frequently with 1-g doses).  
               </p>
<p><span class="routemethod">INCOMPATIBILITIES</span> <span class="incompattype">Solution/additive:</span>
<b>Ringer's lactate,</b> stable in <b>dextrose</b>-containing solutions for only 4 h. <span class="incompattype">Y-site:</span>
<b>Azithromycin, milrinone.</b>
</p>
</td>
</tr>
</table>
<ul>
<li>Store according to manufacturer's recommendations; stability of IV solutions depends on diluent used for reconstitution.</li>
<li>Most IV solutions retain potency for 4 h at 15°30° C (59°86° F) or for 24 h if refrigerated
            at 4° C (39° F). Avoid freezing.
         </li>
</ul>
<h1><a name="adverse">Adverse Effects (<img src="../images/special/greaterorequal.gif"/>1%)</a></h1><span class="typehead">Body as a Whole:</span> Hypersensitivity (rash, fever, chills, dyspnea, pruritus), weakness, oliguria/anuria, polyuria, polyarthralgia; <span class="speceff-common">phlebitis and pain at injection site,</span> superinfections. <span class="typehead">CNS:</span> Seizures, dizziness, confusion, somnolence, encephalopathy, myoclonus, tremors, paresthesia, headache. <span class="typehead">GI:</span>
<span class="speceff-common">Nausea, vomiting,</span> diarrhea, <span class="speceff-life">pseudomembranous colitis</span>, hemorrhagic colitis, gastroenteritis, abdominal pain, glossitis, heartburn. <span class="typehead">Respiratory:</span> Chest discomfort, hyperventilation, dyspnea. <span class="typehead">Skin:</span> Rash, pruritus, urticaria, candidiasis, flushing, increased sweating, skin texture change, facial edema. <span class="typehead">Metabolic:</span> Hyponatremia, hyperkalemia. <span class="typehead">Special Senses:</span> Transient hearing loss; increased WBC, AST, ALT, alkaline phosphatase, BUN, LDH, creatinine; decreased Hgb, Hct, eosinophilia. 
      <h1><a name="interactions">Interactions</a></h1><span class="typehead">Drug:</span>
<b>Aztreonam,</b>
<b>cephalosporins,</b>
<b>penicillins</b> may antagonize the antibacterial effects. 
      <h1><a name="pharmaks">Pharmacokinetics</a></h1><span class="typehead">Distribution:</span> Widely distributed; limited concentrations in CSF; crosses placenta; in breast milk. <span class="typehead">Elimination:</span> 70% of dose excreted in urine within 10 h. <span class="typehead">Half-Life:</span> 1 h. 
      <h1><a name="nursing"><span class="implictitle">Nursing Implications</span></a></h1>
<p><span class="adeffecttitle">Assessment &amp; Drug Effects</span></p>
<ul>
<li>Determine previous hypersensitivity reaction to beta-lactam antibiotics (penicillins and cephalosporins) or to other allergens.</li>
<li>Monitor for S&amp;S of hypersensitivity (see Appendix F). Discontinue drug and notify physician if S&amp;S occur.</li>
<li>Monitor closely patients vulnerable to CNS adverse effects.</li>
<li>Notify physician if focal tremors, myoclonus, or seizures occur; dosage adjustment may be needed.</li>
<li>Monitor for S&amp;S of superinfection (see Appendix F).</li>
<li>Notify physician promptly to rule out pseudomembranous enterocolitis if severe diarrhea accompanied by abdominal pain and
            fever occurs (see Appendix F).
         </li>
<li>
            							Note: Sodium content derived from drug is high; consider in patient on restricted sodium intake.
            						
         </li>
<li>Monitor renal, hematologic, and liver function periodically.</li>
</ul>
<p><span class="eductitle">Patient &amp; Family Education</span></p>
<ul>
<li>Notify physician immediately to report pruritus or symptoms of respiratory distress.</li>
<li>Report pain or discomfort at IV infusion site.</li>
<li>Report loose stools or diarrhea promptly.</li>
<li>Do not breast feed while taking this drug without consulting physician.</li>
</ul>
<hr/>
<p><span class="footer">Common adverse effects in <i>italic</i>, life-threatening effects <u>underlined</u>; generic names in <b>bold</b>; classifications in <small>SMALL CAPS</small>; <img border="0" src="../images/maple.gif"/> Canadian drug name; <img border="0" src="../images/pr.gif"/> Prototype drug</span></p>
</body>